Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Asia-Pacific Gastric Cancer Therapeutics Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies" report to their offering.

The Asia-Pacific gastric cancer market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.

The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.

In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Introduction

2.2 Epidemiology

2.3 Symptoms

2.4 Etiology

2.5 Pathophysiology

2.6 Diagnosis

2.7 Classification and Disease Staging

2.8 Prognosis

2.9 Treatment Guidelines and Options

3 Marketed Products

3.1 Overview

3.2 HER2-Targeted Therapy

3.3 Angiogenesis Inhibitors

3.4 Newer Chemotherapies

3.5 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis

4.1 Overview

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type

4.3 Pipeline by Molecular Target

4.4 Promising Pipeline Candidates

4.5 Comparative Efficacy and Safety of Pipeline Products

4.6 Product Competitive Framework

5 Clinical Trial Analysis

5.1 Failure Rate

5.2 Clinical Trial Size

5.3 Clinical Trial Duration

5.4 Summary of Clinical Trial Metrics

6 Multi-Scenario Forecast

7 Market Dynamics

7.1 Drivers

7.1.1 Increasing Prevalence and Treatment Rate Across All Lines of Therapy in the Metastatic Setting

7.1.2 Promising Drug Pipeline Focused on Targeted Therapies

7.1.3 Launch of Premium-Priced Drugs for the Metastatic Setting

7.1.4 Improved Treatment Options that Extend Duration of Therapy

7.1.5 Increasing Screening Programs and Government Reforms

7.2 Barriers

7.2.1 Lack of Development of Pipeline Agents as Pre-operative and Postoperative Treatments for Resectable Gastric Cancer

7.2.2 Patent Expiration of Herceptin and Patient Share Erosion by Trastuzumab Biosimilars

7.2.3 Affordability and Reimbursement Issues in India and China

8 Deals and Strategic Consolidations

8.1 Licensing Deals

8.2 Co-development Deals

9 Appendix

Companies Mentioned

- AstraZeneca

- Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma)

- Celgene/Taiho

- Eli Lilly

- Gilead Bioscience

- Jiangsu HengRui Medicine

- Kuhnil Pharmaceutical/Daiichi Sankyo

- Merck

- Ono Pharmaceutical/Bristol-Myers Squibb

- Roche

- Taiho

For more information about this report visit

View source version on

Business Wire

Last updated on: 17/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.